Clinical Trial Update: Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma [Phase 1]

View source ↗

Summary

This phase 1 trial assessed safety and preliminary activity of the HDAC inhibitor vorinostat combined with bortezomib in pediatric patients with refractory or r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Brain Stem Glioma
• Childhood Burkitt Lymphoma
• Childhood Central Nervous System Germ Cell Tumor
• Childhood Cerebral Astrocytoma
• Childhood Ependymoma
• Childhood Hodgkin Lymphoma
• Childhood Large Cell Lymphoma
• Childhood Medulloblastoma

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Status: COMPLETED